IHWM
LCTX icon

Iron Horse Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Iron Horse Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-110
Closed – – 223
2021
Q2 		$0 Hold
110
– – ﹤0.01% 203
2021
Q1 		$0 Hold
110
– – ﹤0.01% 195
2020
Q4 		$0 Buy
+110
New +$154 ﹤0.01% 183

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Iron Horse Wealth Management's LCTX Position: Q3 2021 in Review

Iron Horse Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 110 shares.

Iron Horse Wealth Management first reported a position in LCTX in Q4 2020 and held it in 3 quarters. The position peaked at $0 in Q2 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • Iron Horse Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Iron Horse Wealth Management sold 110 Lineage Cell Therapeutics shares in Q3 2021.
  • Iron Horse Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 3 quarters.
  • Iron Horse Wealth Management's Lineage Cell Therapeutics position peaked at $0 in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Iron Horse Wealth Management's 13F filing for Q3 2021, filed 6 Oct 2021.